干旱区生态环境知识资源中心(Arid): A82846B 生产菌株选育及发酵培养基的优化

Arid

	A82846B 生产菌株选育及发酵培养基的优化
其他题名	Breeding of the A82846B-producing Strains and Optimization of Its Fermentation Media
	田勋; 高苹; 刘英; 胡海峰
来源期刊	中国医药工业杂志
ISSN	1001-8255
出版年	2020
卷号	51 期号:1 页码:63-68
中文摘要	以荒漠拟孢囊菌SIPI-HT47为出发菌株,发酵合成奥利万星中间体A82846B。应用紫外和NTG诱变,结合自身抗性及氯化盐耐受筛选,获得1株高产突变株,命名为FH-32-322,发酵效价较出发菌株提高172.5%。通过PB试验、爬坡试验和响应面试验设计优化发酵培养基组成,确定最佳摇瓶发酵配方。在优化后的发酵培养基上,突变株FH-32-322摇瓶发酵效价达到1 013 mg/L,较原工艺提高85.9%。
英文摘要	To synthesize compound of A82846B, a key intermediate of oritavancin, a high producing strain named FH-32-322 was obtained by using UV and NTG mutagenesis based on self-resistance and chloride tolerance from original strain Kibdelosporangium aridum SIPI-HT47. The yielding rate of mutant strain increased 172.5% in fermentation titer compared to SIPI-HT47. After optimized by PB, steepest ascent design, and response surface methodology, the optimum composition of medium for shaking flask fermentation was determined. Under optimized condition, the fermentation titer of A82846B reached up to 1 013 mg/L of shaking flask fermentation, which was 85.9% higher than that of the original strain.
中文关键词	奥利万星 ; 关键中间体 ; 诱变 ; 发酵 ; 响应面
英文关键词	oritavancin key intermediate mutagenesis fermentation response surface
语种	中文
收录类别	CSCD
WOS类目	PHARMACOLOGY PHARMACY
WOS研究方向	Pharmacology & Pharmacy
CSCD记录号	CSCD:6661341
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/316219
作者单位	中国医药工业研究总院上海医药工业研究院;;国药集团健康产业研究院有限公司, ;;, ;;, 上海;;上海 200040;;201203, 中国
推荐引用方式 GB/T 7714	田勋,高苹,刘英,等. A82846B 生产菌株选育及发酵培养基的优化[J],2020,51(1):63-68.
APA	田勋,高苹,刘英,&胡海峰.(2020).A82846B 生产菌株选育及发酵培养基的优化.中国医药工业杂志,51(1),63-68.
MLA	田勋,et al."A82846B 生产菌株选育及发酵培养基的优化".中国医药工业杂志 51.1(2020):63-68.